Form 4 for MRNA Moderna
Accepted 2022-05-20 00:00:00 ET · period of report 2022-05-18 · accession 0000899243-22-019134 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-05-20 | 2022-05-18 | MRNA | AFEYAN NOUBAR | Dir | S - Sale | $138.38 | -10.0K | 2.57M | -0.4% | -$1.38M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-18 | S | D | 10,000 | $138.38 | 2,567,209 | D | — | — | (F2) Includes shares received in prior distributions-in-kind from Flagship VentureLabs IV LLC ("VentureLabs IV"), Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Fund Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") and Flagship Fund IV General Partner LLC ("Flagship Fund IV GP") made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. |